February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
Flutamide helps with prostate cancer and some skin conditions but can harm the liver.
3 citations
,
January 2021 in “Minia Journal of Medical Research” Cyclophosphamide severely damages the intestinal lining in rats.
33 citations
,
May 2017 in “Journal of Clinical Oncology” ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.
5 citations
,
June 2021 in “Journal of neurology, neurosurgery and psychiatry” Taking high doses of Cyproterone acetate significantly increases the risk of meningioma in females.
6 citations
,
September 2015 in “Journal of Medicinal Chemistry” The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.
New steroid derivatives show promise as anticancer agents, even against resistant cells.
3 citations
,
April 2025 in “International Journal of Pharmaceutics” Nanocrystals improve alopecia areata treatment by better targeting hair follicles.
16 citations
,
August 2003 in “Journal of The American Academy of Dermatology” Nitrogen mustard was not very effective for hair regrowth in alopecia areata and has potential skin cancer risk.
137 citations
,
December 2006 in “Arthritis Research & Therapy” Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.
1 citations
,
December 2023 in “Nanomaterials” Combining specific nanoparticles with immune therapy significantly improves cancer treatment.
March 2025 in “Pediatric Rheumatology” Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.
39 citations
,
October 2014 in “Schweizerische medizinische Wochenschrift” Cyclophosphamide has serious side effects, but long-term follow-up can help manage risks.
88 citations
,
July 2009 in “Experimental and Clinical Endocrinology & Diabetes” 16 citations
,
September 1999 in “Journal of Investigative Dermatology Symposium Proceedings”
7 citations
,
January 2017 in “Annals of Dermatology” Oral cyclosporine combined with Pantogar® effectively treats twenty-nail dystrophy.
November 2024 in “Nanomaterials” The nanocrystalline suspension effectively delivers dutasteride over time with minimal inflammation.
44 citations
,
August 1996 in “Drugs & Aging” Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.
April 2025 in “European Journal of Pharmaceutics and Biopharmaceutics” The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.
26 citations
,
January 1992 in “Cancer investigation” N-acetylcysteine and ImuVert can prevent hair loss in rats caused by chemotherapy.
5 citations
,
December 2022 in “Annals Academy of Medicine Singapore” Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.
6 citations
,
December 2021 in “Journal of Cancer Research and Therapeutics” The treatment improved survival and controlled cancer spread but required managing side effects like rashes.
14 citations
,
May 2019 in “Human gene therapy” MC-DNA vector-based gene therapy can temporarily treat CBS deficiency in mice.
1 citations
,
September 1981 in “PubMed” Cyproterone acetate effectively treats virilized women, especially under 35, despite some side effects.
10 citations
,
December 2023 in “International Journal of Nanomedicine” Cell membrane-coated nanoparticles could improve gene therapy by enhancing delivery and targeting of nucleic acids.
4 citations
,
March 2018 in “Journal of labelled compounds & radiopharmaceuticals” A new compound was effective for imaging prostate cancer in rats.
30 citations
,
June 1988 in “Journal of Steroid Biochemistry” Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.
December 2022 in “Jurnal Farmasi Klinik Base Practice” Cyclophosphamide helped 59.4% of children with steroid-resistant nephrotic syndrome but caused side effects in 40.6%.